CTRI/2019/12/022470已完成未知
An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Sugar Free Green in Healthy Normal Sugar Level Overweight and Pre-diabetic Overweight Adult Human Subjects in Controlled Physical Activity Regimen
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1) Age: 18 to 55 yrs
- •2) Sex: Male and/or non-pregnant/ non-lactating females
- •3) Body Mass Index (BMI) of >=25 to <= 30.0 kg/m2
- •4) For Pre-diabetics subjects: Fasting Blood Glucose level from 100-125 mg/dL (called impaired fasting glucose or IFG) and HbA1c levels >=5.7% to <=6.4%
- •5) Subjects willing to follow diet plan
- •6) Subjects willing to reduce their weight and waist circumference
- •7) Subjects with history of stable weight, defined as no significant weight change (less than ±5%) within 03 months prior to enrollment and the physical activity level lesser than 2.0
- •8) Normal renal and liver tests
- •9) Subject must be willing to abstain to eat any other sugar containing products, any other form of sugar usage for the duration of the study
排除标准
- •1) Pregnant female subjects or females planning to get pregnant during study duration
- •2) Subjects having Type 1/ Type 2 Diabetes Mellitus
- •3) Subjects having Insulin Resistance
- •4) Subjects having Lipid Abnormalities
- •5) Subject diagnosed with eating disorders such as bulimia or binge eating
- •6) History of Positive HIV test
- •7) History of Hepatitis B Virus
- •8) Subject with any history of drug and alcohol abuse
- •9) History of Cancer
- •10) History of clinically significant cardiac disease or endocrine abnormalities
研究者
相似试验
尚未招募
4 期
Study to Evaluate the Safety and Efficacy of the Topical Formulation ââ?¬Ë?Vagitone Intimate Hygiene Wash and Vagitone Vaginal Gelââ?¬â?¢ in Female Subjects for Maintaining Vulvovaginal Health and HygieneCTRI/2022/08/045083Aimil Ayouthveda India Ltd
进行中(未招募)
不适用
An open-label study to evaluate the safety and efficacy of three experimental drugs (Ombitasvir/ ABT-450/ Ritonavir and Dasabuvir) in people with genotype 1b hepatitis C virus (HCV) and early liver damage. Experimental means that they have not been approved by any regulatory agency for sale to the public.EUCTR2014-001953-18-BEAbbVie Deutschland GmbH & Co. KG50
进行中(未招募)
1 期
A Study to Evaluate Ombitasvir/ Paritaprevir / Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults.EUCTR2015-003370-33-ITABBVIE DEUTSCHLAND GMBH & CO. KG166
进行中(未招募)
1 期
A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected AdultsEUCTR2015-003370-33-GBAbbVie Deutschland GmbH & Co. KG166
进行中(未招募)
1 期
A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected AdultsEUCTR2015-003370-33-DEAbbVie Deutschland GmbH & Co. KG160
